. 2016 May 28;73(21):4043–4061. doi: 10.1007/s00018-016-2278-y

Table 1.

MDSC levels in association with patient survival

Phenotype	Cancer type	Patient number	Threshold	PT	Treatment after blood draw	Reference population	Refs.
Monocytic MDSCs
CD14⁺HLA-DR⁻CD15⁺CD33⁺CD11b⁺Lin⁻	NSCLC	N = 104 (p = 0.0082)	2.2 %	No	Chemotherapy (±Bevacizumab)	CD11b⁺CD14⁺ cells	[41]
CD14⁺HLA-DR^−/lowCD15⁻CD33⁺CD11b⁺Lin⁻	Prostate cancer	N = 41 (p = 0.13)	NM	Yes	Mix	Live cells	[36]
CD14⁺HLA-DR^−/lowCD15⁻CD33⁺CD11b⁺CD34⁻CD80⁻CD83⁻PD-L1⁻	NSCLC	N = 60 (p < 0.01)	9.43 % or 44.7 cells/µL	No	Chemotherapy	CD14⁺ cells	[40]
CD14⁺HLA-DR^−/lowCD15⁻CD11b⁺	Melanoma	N = 51 (p = 0.007)	2.3 %	Yes	Mix	Live cells	[29]
CD14⁺HLA-DR^−/lowCD11b⁺Lin⁻	Melanoma	N = 68 (p = 0.002)	14.9	Yes	Ipilimumab	Lin⁻CD14⁺CD11b⁺ cells	[31]
CD14⁺HLA-DR^−/lowCD11b⁺Lin⁻	Melanoma	N = 133 (p < 0.001)	11 %	Yes	Mix	Live cells	[69]
CD14⁺HLA-DR^−/lowCD11b⁺	Melanoma	N = 33 (p = 0.08)	2.9 %	No	Peptide Vaccination	CD14⁺ cells	[73]
CD14⁺HLA-DR^−/lowLin⁻	Breast cancer	N = 40 (p = 0.03)	NM	No	Mix	CD45⁺ cells	[71]
	CLL	N = 49 (p = 0.0001)	40 %	No	NM	CD14⁺ cells	[42]
	Melanoma	N = 164 (p < 0.001)	5.1 %	Yes	Ipilimumab	Live cells	[74]
	Prostate cancer	N = 24 (p = 0.0046)	0.3 %	ND	Ipilimumab + GVAX	Live cells	[75]
CD14⁺HLA-DR^−/low	ESCC	N = 76 (p = 0.0036)	2.38 %	No	None	Single cells	[44]
	HCC	N = 123 (p = 0.008)	22 %	No	Radiofrequency ablation	CD14⁺ cells	[38]
	RCC	N = 57 (p = 0.0035)	NM	Yes	Peptide Vaccination	Single cells	[46]
Granulocytic MDSCs
CD15⁺CD14⁻HLA-DR^−/lowCD33⁺CD11b⁺Lin⁻	Gastric cancer	N = 40 (p = 0.024)	4 %	No	Chemotherapy	Total cells	[55]
CD15⁺CD16^low	Lung, breast, gastrointestinal and other	N = 53 (p = 0.001)	293 cells/mL	Yes	NM		[56]
Immature/undefined MDSCs
CD33⁺CD11b⁺CD14⁻HLA-DR⁻Lin⁻	Melanoma	N = 34 (p = 0.0162)	NM	Yes	NM	Live cells	[28]
CD33⁺CD11b⁺CD14⁻HLA-DR⁻	Prostate cancer	N = 62 (p < 0.001)	NM	No	Chemotherapy	Live cells	[58]
CD33⁺CD11b⁺HLA-DR⁻Lin⁻	Breast cancer	N = 26 (p = 0.048)	3.17 %	Yes	Chemotherapy	Total cells	[13]
	Colorectal cancer	N = 25 (p = 0.025)	2.54 %	Yes	Chemotherapy	Total cells	[13]
	Pancreatic, esophageal and gastric cancer	N = 123 (p < 0.001)	2 %	Yes	Mix	Live cells	[23]
	Melanoma	N = 27 (p = 0.03)	NM	No	Ipilimumab	Monocytes	[77]
	Melanoma	N = 69 (p = 0.012)	4.13 %	Yes	NM	Live cells	[59]
CD33⁺CD34⁺CD11b⁺HLA-DR⁻CD14⁻	Hodgkin lymphoma	N = 60 (p < 0.001)	0.0045 × 10⁹/l	ND	Chemotherapy	CD34⁺ cells	[45]
CD33⁺CD2⁻CD19⁻CD45⁺Lin⁻	Ovarian cancer	N = 137 (p = 0.006)	NM	ND	NM	NM	[68]

CLL chronic lymphocytic leukaemia, ESCC esophageal squamous cell carcinoma, HCC hepatocellular carcinoma, NM not mentioned, NSCLC non-small cell lung cancer, PT pretreatment, RCC renal cell carcinoma